CVE-2012-2196

Description

IBM DB2 9.1 before FP12, 9.5 through FP9, 9.7 through FP6, 9.8 through FP5, and 10.1 allows remote attackers to read arbitrary XML files via the (1) GET_WRAP_CFG_C or (2) GET_WRAP_CFG_C2 stored procedure.

Category

5.0
CVSS
Severity: Medium
CVSS 2.0 •
EPSS 0.62%
Vendor Advisory ibm.com Vendor Advisory ibm.com Vendor Advisory ibm.com Vendor Advisory ibm.com Vendor Advisory ibm.com
Affected: n/a n/a
Published at:
Updated at:

References

Link Tags
http://www-01.ibm.com/support/docview.wss?uid=swg1IC84712 vendor advisory
http://www-01.ibm.com/support/docview.wss?uid=swg1IC84751 vendor advisory
http://secunia.com/advisories/49919 third party advisory
http://www.securityfocus.com/bid/54487 vdb entry
http://www-01.ibm.com/support/docview.wss?uid=swg21600837
http://www-01.ibm.com/support/docview.wss?uid=swg1IC84614 vendor advisory
http://www-01.ibm.com/support/docview.wss?uid=swg1IC84750 vendor advisory
http://www-01.ibm.com/support/docview.wss?uid=swg1IC84748 vendor advisory

Frequently Asked Questions

What is the severity of CVE-2012-2196?
CVE-2012-2196 has been scored as a medium severity vulnerability.
How to fix CVE-2012-2196?
To fix CVE-2012-2196, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2012-2196 being actively exploited in the wild?
As for now, there are no information to confirm that CVE-2012-2196 is being actively exploited. According to its EPSS score, there is a ~1% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.